Program
cafelkibart
Also written as “LM-108”, “LM-108 in combination with Toripalimab” and “LM-108 injection”.
In Sino Biopharmaceutical's pipeline, CCR8单抗
. Its studies are mostly in Pancreatic Neoplasms, led by Sino Biopharmaceutical.
Furthest: phase 3, since Jan 7, 20267 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 75 open or running | phase 3since Jan 7, 2026 | Dec 15, 2021 | Dec 2027phase 2 · NCT06821503 |
- Named in Sino Biopharmaceutical’s own pipeline as
LM-108
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2021First study: phase 2 study in Advanced Solid TumorFirst studyNCT05199753 · 78 enrolled · Australia
- Feb 14, 2022Phase 2 study in Advanced Solid TumorNCT05255484 · 24 enrolled · United States
- Aug 24, 2022Phase 2 study in Advanced Solid TumorNCT05518045 · 392 enrolled · China
- Jan 21, 2025Phase 2 study in Advanced Pancreatic CancerNCT06821503 · 72 planned · China
- Feb 9, 20252 phase 2 studies in Advanced Solid TumorNCT06825494, NCT06873854
- Jan 7, 2026Phase 3 study in Locally Advanced or Metastatic GC and GCJ AdenocarcinomaPhase 3 reachedNCT07362186 · 400 planned · China
Ahead
- Dec 2027Primary completion: phase 2 study in Advanced Pancreatic CancerNCT06821503
- Jan 26, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT06873854
- Aug 17, 2028Primary completion: phase 3 study in Locally Advanced or Metastatic GC and GCJ AdenocarcinomaNCT07362186
TargetBeta
“CCR8单抗”the company's pipeline, read by Claude · source
“A monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| CCR8 Inhibitor IPG7236rule | nanjing-immunophage-biotech-co-ltd | phase 2 | 3 |
| denikitugrule | Gilead Sciences | phase 2 | 3 |
| imzokitug | Bristol-Myers Squibb | phase 2 | 2 |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 1 |
| Anti-CCR8 Monoclonal Antibody HC006rule | hc-biopharma-inc | phase 1 | 2 |
| azirkitug | AbbVie | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07362186Locally Advanced or Metastatic GC and GCJ Adenocarcinoma · China | 3 | Recruiting | Aug 17, 2028 | 400 |
| NCT06873854Advanced Solid Tumor · China | 2 | Not yet recruiting | Jan 26, 2028 | 84 |
| NCT06825494Advanced Solid Tumor · China | 2 | Recruiting | Mar 2026 | 194 |
| NCT06821503Advanced Pancreatic Cancer · China | 2 | Recruiting | Dec 2027 | 72 |
| NCT05518045Advanced Solid Tumor · China | 2 | Active, not recruiting | Oct 31, 2026 | 392 |
| NCT05255484Advanced Solid Tumor · United States | 2 | Terminated | Oct 6, 2023 | 24 |
| NCT05199753Advanced Solid Tumor · Australia | 2 | Completed | Dec 31, 2024 | 78 |
How it is read
Names in the registry
- “LM-108”, 4 entries
- “LM-108 in combination with Toripalimab”, 1 entry
- “LM-108 injection”, 1 entry
- “LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine”, 1 entry
- “LM-108 injection 10mg/kg +penpulimab”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.